Covered recipient · General Payments record
SAMY K METYAS
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$282,924.31
604 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $169,156.00 | 74 |
| Consulting Fee | $37,293.00 | 11 |
| Travel and Lodging | $33,871.00 | 92 |
| Honoraria | $30,828.00 | 13 |
| Food and Beverage | $11,736.52 | 411 |
| Education | $39.79 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $70,935.37 | 100 |
| Amgen Inc. | $53,557.42 | 88 |
| Celgene Corporation | $40,881.34 | 41 |
| Horizon Therapeutics plc | $33,796.37 | 61 |
| AbbVie, Inc. | $21,414.96 | 61 |
| Mallinckrodt Enterprises LLC | $18,705.96 | 34 |
| Novartis Pharmaceuticals Corporation | $16,386.27 | 39 |
| Janssen Scientific Affairs, LLC | $14,864.96 | 15 |
| GENZYME CORPORATION | $5,753.29 | 13 |
| Regeneron Healthcare Solutions, Inc. | $4,199.89 | 13 |
| Janssen Biotech, Inc. | $651.45 | 29 |
| E.R. Squibb & Sons, L.L.C. | $309.29 | 29 |
| UCB, Inc. | $294.94 | 11 |
| PFIZER INC. | $264.29 | 23 |
| SANOFI-AVENTIS U.S. LLC | $262.36 | 5 |
| MEDEXUS PHARMA, INC. | $136.09 | 17 |
| Alexion Pharmaceuticals, Inc. | $81.06 | 2 |
| Novo Nordisk Inc | $68.45 | 4 |
| Sobi, Inc | $66.09 | 4 |
| Johnson & Johnson Health Care Systems Inc. | $54.48 | 1 |
| Radius Health, Inc. | $46.84 | 2 |
| GlaxoSmithKline, LLC. | $44.74 | 3 |
| Hikma Pharmaceuticals USA | $37.71 | 2 |
| Grifols USA, LLC | $35.81 | 2 |
| Genentech USA, Inc. | $32.52 | 2 |
| ARBOR PHARMACEUTICALS, INC. | $27.65 | 2 |
| Merck Sharp & Dohme Corporation | $14.71 | 1 |
Page 7 of 13; records 301–350 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SAMY K METYAS
NPI 1831104694 · CMS profile ID 128377
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
COVINA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 7 of 13; records 301–350 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=7#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SAMY K METYAS, NPI 1831104694, CMS profile ID 128377. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 13; records 301–350 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). SAMY K METYAS, NPI 1831104694, CMS profile ID 128377. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 13; records 301–350 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- SAMY K METYAS, NPI 1831104694, CMS profile ID 128377, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 13; records 301–350 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=7#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
604 matching records · $282,924.31 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 301–350 of 604.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $13.96 | 07/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658594680 | CMS |
| Janssen Biotech, Inc. | $31.52 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658594677 | CMS |
| Horizon Therapeutics plc | $10.96 | 07/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691445575 | CMS |
| Horizon Therapeutics plc | $7.05 | 07/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691445571 | CMS |
| Novartis Pharmaceuticals Corporation | $21.01 | 07/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659918691 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.90 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651283247 | CMS |
| Lilly USA, LLC | $20.00 | 07/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658132859 | CMS |
| AbbVie, Inc. | $17.36 | 07/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647744615 | CMS |
| Amgen Inc. | $2,400.00 | 07/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663000801 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.51 | 07/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437047 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.00 | 07/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437049 | CMS |
| Regeneron Healthcare Solutions, Inc. | $29.00 | 07/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437053 | CMS |
| Regeneron Healthcare Solutions, Inc. | $48.00 | 07/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437057 | CMS |
| Mallinckrodt Enterprises LLC | $10.60 | 07/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704809907 | CMS |
| UCB, Inc. | $34.57 | 07/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688367195 | CMS |
| Celgene Corporation | $3,608.00 | 07/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672901389 | CMS |
| Celgene Corporation | $870.40 | 07/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672904405 | CMS |
| Celgene Corporation | $131.67 | 07/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673022941 | CMS |
| GENZYME CORPORATION | $24.83 | 07/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694094065 | CMS |
| Amgen Inc. | $11.25 | 06/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663000743 | CMS |
| Horizon Therapeutics plc | $15.15 | 06/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691445567 | CMS |
| PFIZER INC. | $1.68 | 06/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672460911 | CMS |
| AbbVie, Inc. | $7.36 | 06/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647744559 | CMS |
| Mallinckrodt Enterprises LLC | $532.61 | 06/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704809905 | CMS |
| Novartis Pharmaceuticals Corporation | $697.17 | 06/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659918681 | CMS |
| Novartis Pharmaceuticals Corporation | $2,525.00 | 06/26/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659918683 | CMS |
| Novartis Pharmaceuticals Corporation | $70.65 | 06/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659918685 | CMS |
| ARBOR PHARMACEUTICALS, INC. | $13.63 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697366505 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.20 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651283243 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.30 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651283245 | CMS |
| Amgen Inc. | $11.33 | 06/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663000741 | CMS |
| Novartis Pharmaceuticals Corporation | $15.43 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659918689 | CMS |
| Horizon Therapeutics plc | $1,500.00 | 06/19/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691445563 | CMS |
| MEDEXUS PHARMA, INC. | $1.15 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861203 | CMS |
| MEDEXUS PHARMA, INC. | $12.88 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861205 | CMS |
| Mallinckrodt Enterprises LLC | $2,950.00 | 06/19/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704809903 | CMS |
| Sobi, Inc | $16.92 | 06/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698096101 | CMS |
| Amgen Inc. | $393.25 | 06/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663000963 | CMS |
| Horizon Therapeutics plc | $13.24 | 06/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691445561 | CMS |
| Mallinckrodt Enterprises LLC | $22.12 | 06/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704809899 | CMS |
| Mallinckrodt Enterprises LLC | $641.25 | 06/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704809901 | CMS |
| AbbVie, Inc. | $6.34 | 06/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647744595 | CMS |
| AbbVie, Inc. | $2.11 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647744709 | CMS |
| Amgen Inc. | $89.28 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663000940 | CMS |
| Horizon Therapeutics plc | $16.09 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691445557 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.97 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437027 | CMS |
| Regeneron Healthcare Solutions, Inc. | $36.05 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437031 | CMS |
| Regeneron Healthcare Solutions, Inc. | $258.77 | 06/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437033 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.58 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437037 | CMS |
| Regeneron Healthcare Solutions, Inc. | $48.21 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673437041 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $20,419.16 | 2 |
| PY2025 | Principal investigator | $3,432,728.17 | 53 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $3,345,685.96 | 90 |
| PY2023 | Principal investigator | $813,878.89 | 118 |
| PY2022 | Recipient | $314.00 | 1 |
| PY2022 | Principal investigator | $1,354,175.08 | 247 |
| PY2021 | Recipient | $65.00 | 1 |
| PY2021 | Principal investigator | $1,151,466.83 | 155 |
| PY2020 | Recipient | $825.80 | 2 |
| PY2020 | Principal investigator | $803,381.38 | 113 |
| PY2019 | Principal investigator | $737,702.55 | 112 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
55 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,517.39 | 12/17/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223289890 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,000.00 | 11/24/2025 | Non-covered Recipient Entity MEDVIN CLINICAL RESEARCH | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment | No dispute reported | 06/30/2026 | 1190308938 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,938.81 | 11/19/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430932 |
| Principal investigator 1 | ABBVIE INC. | $7,485.00 | 11/05/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | No dispute reported | 06/30/2026 | 1202522279 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,853.60 | 11/05/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192187385 |
| Principal investigator 1 | ABBVIE INC. | $8,200.00 | 10/30/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | No dispute reported | 06/30/2026 | 1202519775 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 10/22/2025 | Non-covered Recipient Entity Biovin Enterprises Llc | Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) | No dispute reported | 06/30/2026 | 1226093105 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,205.58 | 10/22/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246430930 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,954.80 | 10/13/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246430946 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 10/10/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286703 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 10/10/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286705 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,812.52 | 10/02/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246430940 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,740.58 | 10/01/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286151 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,945.97 | 09/12/2025 | Non-covered Recipient Entity Biovin Enterprises Llc | Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) | No dispute reported | 06/30/2026 | 1226093009 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,113.88 | 09/10/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430942 |
| Principal investigator 1 | American Regent | $157,665.35 | 09/03/2025 | Non-covered Recipient Entity Biovin Enterprise LLC | TPX-100 | No dispute reported | 06/30/2026 | 1232689947 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,926.80 | 09/03/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192187938 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $479.50 | 09/03/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223284919 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $36,885.00 | 08/26/2025 | Non-covered Recipient Entity MEDVIN CLINICAL RESEARCH | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | No dispute reported | 06/30/2026 | 1190308940 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,225.94 | 08/20/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223284385 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28,296.00 | 08/18/2025 | Non-covered Recipient Entity Biovin Enterprises LLC Medvin Clinical Research | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220809669 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $462.00 | 08/15/2025 | Non-covered Recipient Entity Biovin Enterprises Llc | Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) | No dispute reported | 06/30/2026 | 1226093024 |
| Principal investigator 1 | Amgen Inc. | $143,671.00 | 08/13/2025 | Non-covered Recipient Entity MEDVIN CLINICAL RESEARCH | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246644364 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $120.00 | 08/13/2025 | Non-covered Recipient Entity Biovin Enterprises Llc | Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) | No dispute reported | 06/30/2026 | 1226093019 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26,096.00 | 07/29/2025 | Non-covered Recipient Entity Biovin Enterprises LLC Medvin Clinical Research | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis | No dispute reported | 06/30/2026 | 1220809667 |
| Principal investigator 1 | Amgen Inc. | $2,167.50 | 07/28/2025 | Non-covered Recipient Entity MEDVIN CLINICAL RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246644351 |
| Principal investigator 1 | Amgen Inc. | $146.33 | 07/28/2025 | Non-covered Recipient Entity SAMY METYAS MD INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246647597 |
| Principal investigator 1 | Eli Lilly and Company | $17,892.00 | 07/07/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187880825 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $12,000.00 | 07/07/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430936 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $12,000.00 | 07/07/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430938 |
| Principal investigator 1 | Eli Lilly and Company | $104,132.00 | 07/01/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187876121 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,000.00 | 06/25/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | No dispute reported | 06/30/2026 | 1246430926 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,383.88 | 06/25/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430928 |
| Principal investigator 1 | Amgen Inc. | $363,045.18 | 04/28/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246639733 |
| Principal investigator 1 | Eli Lilly and Company | $2,677.13 | 04/23/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187880821 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,563.70 | 04/23/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430944 |
| Principal investigator 1 | UCB SA | $71,983.50 | 04/22/2025 | Non-covered Recipient Entity Medvin Clinical Research | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246659474 |
| Principal investigator 1 | Amgen Inc. | $156,750.68 | 04/18/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639719 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 04/16/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223278128 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,408.75 | 04/09/2025 | Non-covered Recipient Entity Biovin Enterprises Llc | Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) | No dispute reported | 06/30/2026 | 1226092972 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $208.22 | 03/26/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246430948 |
| Principal investigator 1 | Eli Lilly and Company | $4,281.00 | 03/10/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187874791 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,542.61 | 03/10/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246430934 |
| Principal investigator 1 | Eli Lilly and Company | $10,436.00 | 02/18/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187874789 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,853.60 | 02/05/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192187380 |
| Principal investigator 1 | Eli Lilly and Company | $159,180.00 | 02/04/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187880827 |
| Recipient | Amgen Inc. | $10,872.75 | 01/29/2025 | Covered Recipient Physician | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State | No dispute reported | 06/30/2026 | 1246637224 |
| Principal investigator 1 | Eli Lilly and Company | $2,717.45 | 01/27/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187876175 |
| Recipient | Amgen Inc. | $9,546.41 | 01/22/2025 | Covered Recipient Physician | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246637226 |
| Principal investigator 1 | Eli Lilly and Company | $52,953.00 | 01/21/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187880815 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $96.24 | 01/15/2025 | Non-covered Recipient Entity MEDVIN CLINICAL RESEARCH | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | No dispute reported | 06/30/2026 | 1190301683 |
| Principal investigator 1 | Amgen Inc. | $1,883,008.16 | 01/14/2025 | Non-covered Recipient Entity MEDVIN CLINICAL RESEARCH | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246644381 |
| Principal investigator 1 | Eli Lilly and Company | $4,890.30 | 01/09/2025 | Non-covered Recipient Entity BIOVIN ENTERPRISES LLC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187880831 |
| Principal investigator 1 | Amgen Inc. | $36,267.72 | 01/02/2025 | Non-covered Recipient Entity MEDVIN CLINICAL RESEARCH - COVINA | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246644343 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Medvin Clinical Research Covina | sGC activator in SSc patients | No dispute reported | 06/30/2026 | 1220679522 |